| Date | Title | | | 08/12/10 | PharmAthene Reports Second Quarter 2010 Financial and Operational Results| ANNAPOLIS, Md., Aug 12, 2010 /PRNewswire via COMTEX/ --PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the second quarter and six months ended June 30, 2010.
For the second quarter of 2010, PharmAthene recognized revenues of $4.8 million compared to $8.1 million in the same period of 2009. For the six months ended June 30, 2010 and 2009, respectively, Ph... |
|  | | 08/05/10 | PharmAthene to Host Second Quarter 2010 Conference Call and Webcast on Thursday, August 12, 2010| ANNAPOLIS, Md., Aug 05, 2010 /PRNewswire via COMTEX/ --PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the second quarter of 2010 will be released on Thursday, August 12, 2010.
PharmAthene management will be hosting a conference call to discuss its second quarter 2010 financial results. The call is scheduled to begin at 4:30 p.m. Eastern Time on Thursday, Augus... |
| | | 07/30/10 | PharmAthene Provides Update on NYSE Amex Listing Compliance Plan| ANNAPOLIS, Md., July 30, 2010 /PRNewswire via COMTEX/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that on July 26, 2010 it received a letter from the NYSE Amex LLC, stating that PharmAthene is not in compliance with the continued listing standards specified in Sections 1003(a)(i), (ii) and (iii) of the NYSE Amex Company Guide, because it has stockholders' equity of less than $2.0 million, ... |
| | | 07/23/10 | PharmAthene Completes Previously Announced Registered Direct Offering| Sells $3.9 Million Shares to a Sole Institutional Investor
ANNAPOLIS, Md., July 23, 2010 /PRNewswire via COMTEX/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has completed the sale of $3.9 million of its common stock and warrants to a single existing institutional investor in a registered public offering. The offering was previously announced on July 20, 2010.
Under the terms ... |
| | | 07/20/10 | PharmAthene Announces $3.9 Million Registered Direct Offering| ANNAPOLIS, Md., July 20, 2010 /PRNewswire via COMTEX/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has entered into a purchase agreement to sell $3.9 million of its common stock and warrants to an existing institutional investor in a registered public offering.
Under the terms of the purchase agreement, PharmAthene will sell an aggregate of 2,785,714 newly issued shares of its com... |
| | | 07/15/10 | PharmAthene Presents New Data for Lyophilized rPA Anthrax Vaccine Showing Enhanced Immunogenicity| New Formulation Could Offer Improvements in Cost-Effectiveness and Convenience for the U.S. Government's Stockpile of Biodefense Countermeasures
ANNAPOLIS, Md., July 15, 2010 /PRNewswire via COMTEX/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced results from a New Zealand White Rabbit study showing that its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine was more immunogeni... |
| | | 07/08/10 | PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health| ANNAPOLIS, Md., July 8, 2010 /PRNewswire via COMTEX/ -- PharmAthene, Inc. (NYSE: Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it continues to make solid progress in its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine development program. The Company has recently demonstrated that its lyophilized rPA vaccine candidate is structurally stable and potent at various temperatures up to and including 7... |
| | | 06/09/10 | U.S. Government Accountability Office Denies Competitor Protest of SparVax(TM) Contract Modification| ANNAPOLIS, Md., June 9, 2010 /PRNewswire via COMTEX/ --PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the U.S. Government Accountability Office (GAO) has denied a competitor's protest, challenging a previously announced contract modification for up to $78.4 million for the Company's recombinant rPA anthrax vaccine, SparVax(TM). As a result of t... |
| | | 06/01/10 | PharmAthene to Present at the Noble Financial Sixth Annual Equity Conference on Monday, June 7, 2010| ANNAPOLIS, Md., June 1, 2010 /PRNewswire via COMTEX/ --PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Company will present at the Noble Financial Sixth Annual Equity Conference 'ONTRACK 2010' on Monday, June 7, 2010 at 4:00 p.m. ET in Room 3 - Piquet. The Company's presentation will be available via webcast under the Investor Relations sectio... |
| | | 05/11/10 | PharmAthene Reports First Quarter 2010 Financial and Operational Results| ANNAPOLIS, Md., May 11, 2010 /PRNewswire via COMTEX/ --PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the first quarter ended March 31, 2010.
For the first quarter of 2010, PharmAthene recognized revenue of $3.1 million compared to $5.5 million in the same period of 2009. Revenues for the most recent quarter consisted primarily of contract funding from the ... |
| | | 05/05/10 | PharmAthene to Host First Quarter 2010 Conference Call and Webcast on Tuesday, May 11, 2010| ANNAPOLIS, Md., May 5 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the first quarter of 2010 will be released on Tuesday, May 11, 2010.
PharmAthene management will be hosting a conference call to discuss its first quarter 2010 financial results. The call is scheduled to begin at 4:30 p.m. Eastern Time on Tuesday, May 11, 2010, and is exp... |
| | | 05/04/10 | PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference| ANNAPOLIS, Md., May 4, 2010 /PRNewswire via COMTEX/ --PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that the Company's Interim CEO, Eric I. Richman, will be participating on a special biosecurity panel presentation promoting the critical interrelationship between government, academia and industry in the development of medical countermeasures vital to our nation's biosecurity.
The panel prese... |
| | | 05/03/10 | PharmAthene Appoints Eric I. Richman as Interim Chief Executive Officer| ANNAPOLIS, Md., May 3, 2010 /PRNewswire via COMTEX/ --PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that the Company's Board of Directors has appointed Eric I. Richman to the position of Interim Chief Executive Officer replacing David Wright, who has submitted his resignation.
"PharmAthene's Board of Directors is pleased to appoint Eric Richman as the Company's new Interim Chief Executive Off... |
| | | 04/28/10 | PharmAthene Appoints Mitchel Sayare, Ph.D. to the Company's Board of Directors| ANNAPOLIS, Md., April 28, 2010 /PRNewswire via COMTEX/ --PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced the appointment of Mitchel Sayare, Ph.D. to PharmAthene's Board of Directors, increasing the company's Board to nine members.
Dr. Sayare most recently served as Chairman and Chief Executive Officer of ImmunoGen, a publicly traded biotechnology company engaged in the research and development... |
| | | 04/08/10 | PharmAthene to Raise $2.5 Million From a Single Existing Investor in a Registered Direct Financing| ANNAPOLIS, Md., April 8, 2010 /PRNewswire via COMTEX/ --PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that a single existing institutional investor has agreed to purchase approximately $2.5 million of its common stock and warrants in a registered public offering.
Under the terms of the purchase agreement, PharmAthene will sell an aggregate of 1,666,668 newly issued shares of its common stock ... |
| | | 04/05/10 | PharmAthene Appoints Industry Leader Thomas R. Fuerst Chief Scientific Officer| Seasoned R&D and Manufacturing Executive Brings Over Two Decades of Specialized Experience to PharmAthene
ANNAPOLIS, Md., April 5, 2010 /PRNewswire via COMTEX/ --PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced the appointment of Thomas R. Fuerst, Ph.D., as the company's Senior Vice President, Chief Scientific Officer. In this newly created role, Dr. Fuerst will oversee PharmAthene's researc... |
| | | 03/30/10 | PharmAthene Appoints Eric I. Richman as President and Chief Operating Officer and Announces Senior Management Promotions| ANNAPOLIS, Md., March 30, 2010 /PRNewswire via COMTEX/ --PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that the Company's Board of Directors has appointed Eric I. Richman to the position of President and Chief Operating Officer. Previously Senior Vice President, Business Development and Strategic Planning, in this new role, Mr. Richman will assume management oversight of all day-to-day operati... |
| | | 03/23/10 | PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies| ANNAPOLIS, Md., March 23, 2010 /PRNewswire via COMTEX/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the year ended December 31, 2009.
For the year ended December 31, 2009 PharmAthene recognized revenues of $27.5 million compared to $32.9 million for the year ended December 31, 2008. Revenues for both periods consisted primarily of contract funding from... |
| | | 03/22/10 | PharmAthene to Provide Update on SparVax™ Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010| ANNAPOLIS, Md., March 22, 2010 /PRNewswire via COMTEX/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that in addition to its year end results, it will provide an update on the contract modification suspension it received on Friday, March 19, 2010.
PharmAthene is pursuing various options to move forward under the contract modification announced on February 23, 2010 to its existing contract ... |
| | | 03/19/10 | PharmAthene Contract Modification Subject to Suspension Pending Ruling on Competitor Protest| ANNAPOLIS, Md., March 19, 2010 /PRNewswire via COMTEX/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that pursuant to the Federal Acquisition Regulations and pending a ruling in a protest recently filed by a competitor the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), ha... |
| | | 03/16/10 | PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010| ANNAPOLIS, Md., March 16, 2010 /PRNewswire via COMTEX/ -- PharmAthene, Inc. (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the year ended 2009 will be released on Tuesday, March 23, 2010.
PharmAthene management will host a conference call to discuss its year end financial results. The call is scheduled to begin at 4:30 p.m. Eastern Time on Tuesday, March 23, 2010, and is expected to las... |
| | | 03/09/10 | PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010| ANNAPOLIS, Md., March 9, 2010 /PRNewswire via COMTEX/ -- PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Company will present at the Roth Capital Partners Growth Stock Conference in Laguna Niguel, California on Monday, March 15, 2010 at 1:30 p.m. P.T. To access the Company's presentation via webcast, go to: http://www.wsw.com/webcast/roth23/pi... |
| | | 02/24/10 | Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria| New Valortim(R) Data Presented at the 8th Annual ASM Biodefense and Emerging Diseases Research MeetingANNAPOLIS, Md., Feb 24, 2010 /PRNewswire via COMTEX/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new data from the Company's Valortim(R) anthrax anti-toxin program were presented at the 8th Annual ASM Biodefense and Emerging Diseases Research Meeting, held in Baltimore, Maryland, Feb... |
| | | 02/23/10 | PharmAthene Awarded up to Additional $78.4 Million Under Existing Contract for Advanced Development of SparVax(TM) Anthrax Vaccine| ANNAPOLIS, Md., Feb 23, 2010 /PRNewswire via COMTEX/ -- PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA) has modified its existing research and development contract with PharmAthene providing for up to a total of $78.4 mill... |
| | | 02/01/10 | PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine| ANNAPOLIS, Md., Feb 01, 2010 /PRNewswire via COMTEX/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has submitted a White Paper in response to the Broad Agency Announcement (Solicitation Number: BAA-BARDA-09-34) issued by the Biomedical Advanced Research and Development Authority (BARDA) for the Advanced Research and Development of Chemical, Biological, Radiological and Nuclear Medic... |
| | | 01/05/10 | PharmAthene Updates Status of BARDA rPA Contract Discussions| ANNAPOLIS, Md., Jan 05, 2010 /PRNewswire-FirstCall via COMTEX/ -- PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, today commented on a Special Notice published by the US Department of Health and Human Services (DHHS), Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA) on December 29, 2009. This Special Not... |
| |
|
